Treatment of malignant hypercalcaemia with aminohexane bisphosphonate (neridronate)
1994

Treatment of Malignant Hypercalcaemia with Aminohexane Bisphosphonate

Sample size: 20 publication Evidence: moderate

Author Information

Author(s): N.P. O'Rourke, E.V. McCloskey, S. Rosini, R.E. Coleman, J.A. Kanis

Primary Institution: University of Sheffield, UK

Hypothesis

Can aminohexane bisphosphonate effectively treat hypercalcaemia due to malignancy?

Conclusion

Aminohexane bisphosphonate is effective in treating tumor-induced hypercalcaemia with rapid onset and low toxicity.

Supporting Evidence

  • All 20 patients experienced a fall in serum calcium after treatment.
  • 65% of patients achieved normocalcaemia.
  • The treatment was associated with a significant decrease in fasting urinary calcium excretion.

Takeaway

This study shows that a medicine called aminohexane bisphosphonate can help lower high calcium levels in cancer patients, and it doesn't make people feel very sick.

Methodology

Twenty patients with hypercalcaemia were treated with a single infusion of 125 mg of aminohexane bisphosphonate, and serum and urine biochemistry were measured before and after treatment.

Limitations

The follow-up numbers were low for some time points, and eight patients died within 28 days of treatment.

Participant Demographics

10 men and 10 women, mean age 61.3 years, with various types of malignancies.

Statistical Information

P-Value

0.001

Statistical Significance

p<0.001

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication